References: 1. Trudhesa. Prescribing information. Impel Pharmaceuticals; 2021. 2. Shrewsbury SB, Hoekman J, Jeleva M. Patient acceptability of a novel upper nasal delivery system for dihydroergotamine mesylate using the Precision Olfactory Delivery (POD®) device – results from the open-label STOP 301 trial. Poster presented at: American Headache Society Virtual Annual Scientific Meeting, June 3-6, 2021. 3. Data on File. Impel Pharmaceuticals. 2020.